Sign In
Buy PTCT
$68.68
+0.450 (+0.660%)
At Close: Jun 03, 2026
John Hussman's Strategic Moves: Qualcomm Inc. Takes Center Stage with 1.13% Portfolio Impact
01:01pm, Monday, 02'nd Feb 2026
Exploring the Investment Strategies of John Hussman (Trades, Portfolio) in Q4 2025 John Hussman (Trades, Portfolio) recently submitted the 13F filing for the f
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of “Moderate Buy” by Analysts
01:43am, Monday, 02'nd Feb 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the sixteen ratings firms that are covering the company, MarketBeat Ratings reports. One an
Universal Beteiligungs und Servicegesellschaft mbH Has $8.11 Million Stock Holdings in PTC Therapeutics, Inc. $PTCT
05:48am, Monday, 26'th Jan 2026
Universal Beteiligungs und Servicegesellschaft mbH increased its position in PTC Therapeutics, Inc. (NASDAQ: PTCT) by 6.2% in the third quarter, according to the company in its most recent Form 13F fi
Campbell & CO Investment Adviser LLC Has $205,000 Stock Position in PTC Therapeutics, Inc. $PTCT
03:44am, Sunday, 25'th Jan 2026
Campbell and CO Investment Adviser LLC cut its holdings in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 77.5% in the third quarter, according to its most recent filing with the Securities and Ex
QRG Capital Management Inc. Takes Position in PTC Therapeutics, Inc. $PTCT
07:17am, Tuesday, 20'th Jan 2026
QRG Capital Management Inc. acquired a new position in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) during the third quarter, according to the company in its most recent Form 13F filing with the Se
PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:56pm, Monday, 12'th Jan 2026
PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
08:30am, Monday, 12'th Jan 2026
– Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M – – Unaudited 2025 total product and royalty revenue of approximately $823M, exceeding guidance �
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CFO Sells $164,596.05 in Stock
06:24am, Sunday, 11'th Jan 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) CFO Pierre Gravier sold 2,139 shares of the business's stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an av
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CEO Sells $233,679.68 in Stock
06:24am, Sunday, 11'th Jan 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) CEO Matthew Klein sold 3,016 shares of PTC Therapeutics stock in a transaction dated Wednesday, January 7th. The stock was sold at an average pr
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 08'th Jan 2026
WARREN, N.J., Jan. 8, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 2, 2026, the company approved 300 restricted stock units ("RSUs"), each representing the r
PTC Therapeutics (NASDAQ:PTCT) CEO Matthew Klein Sells 8,089 Shares of Stock
05:38am, Saturday, 03'rd Jan 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) CEO Matthew Klein sold 8,089 shares of PTC Therapeutics stock in a transaction on Tuesday, December 30th. The stock was sold at an average price
What's Going On With Royalty Pharma Stock Wednesday?
10:47am, Wednesday, 31'st Dec 2025
Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.
Eric Pauwels Sells 20,508 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock
04:44am, Thursday, 25'th Dec 2025
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) insider Eric Pauwels sold 20,508 shares of the business's stock in a transaction that occurred on Friday, December 19th. The shares were sold at
– Indication includes all ages and the full spectrum of disease severity – – First Japan product approval for PTC – WARREN, N.J. , Dec. 22, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:
PTC Therapeutics, Inc. $PTCT Shares Sold by Assenagon Asset Management S.A.
03:16am, Monday, 22'nd Dec 2025
Assenagon Asset Management S.A. lessened its position in PTC Therapeutics, Inc. (NASDAQ: PTCT) by 83.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutiona
